Prognostic Value of the Pretreatment Lung Immune Prognostic Index in Advanced Small Cell Lung Cancer Patients Treated With First-Line PD-1/PD-L1 Inhibitors Plus Chemotherapy

Prognostic Value of the Pretreatment Lung Immune Prognostic Index in Advanced Small Cell Lung Cancer Patients Treated With First-Line PD-1/PD-L1 Inhibitors Plus Chemotherapy

BackgroundLung immune prognostic index (LIPI) refers to a biomarker combining derived neutrophil-to-lymphocyte ratio (dNLR) and lactate dehydrogenase (LDH). Its prognostic effect on advanced small cell lung cancer (SCLC) patients receiving programmed cell death 1/programmed cell death ligand-1 (PD-1...

Full description

Bibliographic Details
Main Authors: Lingling Li, Chenghui Pi, Xin Yan, Jiangyue Lu, Xuhui Yang, Chunyu Wang, Xiaoyan Li, Sujie Zhang, Zhibo Zhang, Yi Sun, Yi Hu
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-10-01
Series:Frontiers in Oncology
Subjects:
small cell lung cancer
immune checkpoint inhibitor
first-line
lung immune prognostic index
prognosis
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.697865/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.697865/full

Similar Items